Galleri Test Adoption Accelerates, Driving 28% U.S. Revenue Growth and 39% Volume Surge for GRAIL
Record-Setting Galleri Test Uptake: 45,000+ Sold in Q3, 28% U.S. Revenue Growth
GRAIL (NASDAQ: GRAL) delivered a standout third quarter in 2025, reporting a 28% year-over-year rise in U.S. Galleri revenue to $32.6 million, driven by more than 45,000 Galleri multi-cancer early detection tests sold—up 39% from the same period last year. Total company revenue increased 26% to $36.2 million, signaling growing acceptance of GRAIL's proactive cancer screening solutions in the U.S. and abroad.
Efficiency Gains: Smaller Losses and Substantial Improvement in Key Metrics
Operating efficiency improved across the board. GRAIL reduced its net loss to $89.0 million, a 29% improvement over the prior year, and narrowed its gross loss by 38% to $13.7 million. Adjusted EBITDA showed a marked uptick, landing at $(71.7) million, or 34% better than the third quarter of 2024. The company also grew its non-GAAP adjusted gross profit by 69% to $20.0 million.
| Metric | Q3 2025 | Q3 2024 | % Change |
|---|---|---|---|
| U.S. Galleri Revenue ($M) | 32.6 | 25.4 | +28% |
| Galleri Tests Sold | 45,000+ | ~32,400 | +39% |
| Total Revenue ($M) | 36.2 | 28.7 | +26% |
| Adjusted Gross Profit ($M) | 20.0 | 11.8 | +69% |
| Net Loss ($M) | (89.0) | (125.7) | +29% |
| Adjusted EBITDA ($M) | (71.7) | (108.2) | +34% |
Strong Clinical Data and International Partnerships Signal Expanding Opportunity
The company is buoyed by compelling data: Results from the PATHFINDER 2 and SYMPLIFY studies show Galleri can find more cancers—many without standard screening—at earlier stages. Key Q3 study findings included a sevenfold increase in detected cancers when Galleri is used alongside recommended screenings, and a positive predictive value (PPV) of 61.6% with 99.6% specificity in a general screening population. Notably, more than three-quarters of detected cancers lacked a standard screening method, underlining Galleri’s potential to address critical diagnostic gaps.
GRAIL continues to make global strides, cementing collaborations with Samsung to expand into key Asian markets and launching Galleri in Canada via Medcan and Manulife’s innovative partnership. A recently completed $325 million equity private placement—along with a $110 million Samsung investment—brings GRAIL's total cash position to over $850 million, providing operational runway well into the next decade.
Upcoming Milestones: PMA Submission in Q1 2026 and Analyst Day Ahead
GRAIL expects to submit a premarket approval (PMA) application for Galleri to the FDA in Q1 2026, a move that could unlock broader adoption in clinical practice. Meanwhile, the company’s Analyst Day—set for November 13, 2025—offers a venue for deeper insight into growth drivers and long-term strategy.
Takeaway: Momentum, Evidence, and Financial Flexibility Support GRAIL’s Ambitious Vision
With rapid U.S. adoption, mounting clinical evidence, improving operating metrics, and a cash runway extending into 2030, GRAIL appears well positioned to redefine multi-cancer early detection. For those watching the convergence of genomics and oncology, Galleri’s next chapters—and the Q1 2026 PMA milestone—will be important signals to watch.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI